bemarituzumab
Five Prime Therapeutics,amgen
['bemarituzumab']
bemarituzumab for previously untreated advanced gc/gej cancer: final analysis of phase 2 trial (fight) at #wcgic23 mpfs by 2.1 &amp; mos by 5.7 mo with bemarituzumab/folfox6 compared to folfox6 only efficacy in ihc 2+/3+ with 10% tc staining 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology